"World's First Biotech Merchant Developer"Website homepage noted "Aug 16th" ... "We are in process of turning this company into the world's first biotech merchant developer".
Aug 16th is when the BCR acquistion would be completed ie marking the start of a new evolution of IMM. "New" as in preparation for further acquistion/partnerships of good potential biotechs.
I believe that such acquistions/partnerships are not only limited to Canada or US due to three hints. Developments in asia.
On Mar 10/00 China Post, IMM's commercial director, Ron Kertesz, viewed high potential in Taiwan & South Korea for biotech. Taiwan & South Korea have excellent prospects in biotech due to strength of academic & market research & development. He anticipated that IMM would make a few partnerships in South Korea.
BCR has branches in Canada, US, & Hong Kong. I suspect that BCR acquistion not only acts as a catalyst for IMM due to its financial stability, excellent infrastructure, & proven track record in incubating tech, but also provides as a gateway for market penetration in Hong Kong ie asia.
The last clue came from the word "world" from "world's first biotech merchant developer". This would suggest that IMM is looking at international market not just local or national market. Consider that Canada only represents 3% of world market, developments into rest of the world esp asia would add significant value for IMM.
Without BCR acquistion, each IMM's share would have about than $0.20/share in cash. Once BCR acquistion is completed, IMM would have more than $0.20/share in cash since BCR generates over $7 million each year.
It three main projects namely AIDS (IF7), Asthma (BP1), Alzheimer Disease (AD2) should also add significant value to IMM stock. IF7 Phase I/II is expected to start soon, Q3 of 2000. Once this project starts clinical phase, we would be able to see significant rise in IMM stock as IF7 targets at combating AIDS virus including mutant strains. There is also a good chance of IF7 being tagged as fast-track due to that health minister intends to fast-track drugs used for treatment of AIDS. And results for AD2 should be available in Q1 of 2001. There is also a high possibility that IMM's AD2 drug would be tagged as fast-track due to that it already has a proven long history of safety & that current treatments are unsuccessfully ie AD2 could stop the pregression of Alzheimer Disease instead of just "improving" memory.
A health-related website kind of like WebMD would be launched soon in Q3. This also add significant value to IMM since no biotech has or will be expected to launch a website like this due to limited scientific advisory. As a note, IMM has a global scentific network of advisors.
I believe that IMM would rally very soon, within 2-3 weeks. Then in the fall, there should be tons of PR waiting for us. IMM would be in $1.20 range before fall & could be as high as $4.00-5.00 by year end.
You'll definitely would not want to miss out on IMM ... you're regret if you do cos' it could increase by over 6 times by year end.